2020 Year in Review: Non–Small-Cell Lung Cancer

Patients with untreated advanced NSCLC with EGFR mutations achieved improved progression-free survival with treatment with gefitinib and carboplatin plus pemetrexed compared with gefitinib alone.

Researchers report higher overall response rate, median duration of response, and median progression-free survival in treatment-naïve patients with a MET exon 14 skipping mutation compared with previously treated patients.

Researchers reported improved overall survival in patients with nonsquamous non–small-cell lung cancer with EGFR mutations.

Tarloxotinib treatment was well tolerated and sizeable percentages of patients in both study cohorts achieved either partial response or stable disease.

Overall response rate, duration of response, and media progression-free survival were highest in the group of treatment-naïve patients with T790M negativity and any MET mutation.

Over the past year, the COVID-19 pandemic has ushered in unprecedented changes in the practice of medicine and dissemination of treatment advances presented in scientific forums.

Improved progression-free survival and overall survival in patients who received upfront stereotactic radiotherapy and TKI treatment should prompt additional study.

Previously untreated patients and those who had received prior intracranial radiotherapy responded to selpercatinib treatment.

Treatment was well tolerated and also associated with delayed progression in previously treated patients with NSCLC and MET^Amp/Ex14Δ.

Dual treatment with ramucirumab and erlotinib produced similar results in patients with ex21 and ex19 mutations.